<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="215">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101085</url>
  </required_header>
  <id_info>
    <org_study_id>SEAD2</org_study_id>
    <nct_id>NCT03101085</nct_id>
  </id_info>
  <brief_title>S-Equol in Alzheimer's Disease 2 Trial</brief_title>
  <acronym>SEAD2</acronym>
  <official_title>S-Equol in Alzheimer's Disease 2 (SEAD2) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Russell Swerdlow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ausio Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      By doing this study researchers hope to learn if S-equol, a compound that acts like estrogen&#xD;
      in the body, causes an increase in mitochondrial activity. Researchers also hope to determine&#xD;
      the safety and tolerability of a therapeutic dose of S-equol and whether or not it influences&#xD;
      cognition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2017</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in cytochrome oxidase/citrate synthase (COX/CS) activity</measure>
    <time_frame>One Month</time_frame>
    <description>Measured as the mean intra-individual COX/CS activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety laboratories evaluation and participant/study partner reporting of symptoms or adverse events</measure>
    <time_frame>Month 4</time_frame>
    <description>Measured as adverse events reported over the course of the study (safety labs, physical and neurological exams, vital signs, signs and symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA) Determine if S-equol influences participant scores.</measure>
    <time_frame>Months 2, 3, 4</time_frame>
    <description>Scale range: 0-30 (higher score indicates better result)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-Cognitive Portion (ADASCog-11) Determine if S-equol influences participant scores.</measure>
    <time_frame>Months 2, 3, 4</time_frame>
    <description>Scale range: 0-70 (lower score indicates better result)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Logical Memory Test (LMT) - immediate and delayed recall Determine if S-equol influences participant scores.</measure>
    <time_frame>Months 2, 3, 4</time_frame>
    <description>Scale range: 0-25 (higher score indicates better result)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroop Test Determine if S-equol influences participant scores.</measure>
    <time_frame>Months 2, 3, 4</time_frame>
    <description>Scale range: 0-unlimited (higher score indicates better result)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern of COX activity changes while on the active treatment versus placebo arms of this crossover study.</measure>
    <time_frame>Months 1, 3, 4</time_frame>
    <description>Pts will categorically be defined as responders or non-responders depending on the slope of COS/CS activity change.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>S-equol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive S-equol 50mg twice daily for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matched placebo pill to take twice daily for one month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-equol</intervention_name>
    <description>S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules</description>
    <arm_group_label>S-equol</arm_group_label>
    <other_name>AUS-131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules matched in size and color to S-equol capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of Alzheimer's Disease (AD)&#xD;
&#xD;
          -  Have a study partner who has a close relationship with the participant and will attend&#xD;
             study visits with the participant&#xD;
&#xD;
          -  Do not possess an Alkylphenol ethoxylates 4 (APOE4) variant of the APOE gene&#xD;
&#xD;
          -  Speak English as their primary language&#xD;
&#xD;
          -  Have not had any medication changes within the past 30 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Reside in a nursing home or dementia special care unit&#xD;
&#xD;
          -  Have a potentially confounding, serious medical risk such as insulin-requiring&#xD;
             diabetes, any history of cancer that required a chemotherapy or radiation therapy&#xD;
             intervention within the past 5 years, or a recent cardiac event&#xD;
&#xD;
          -  Have any clinically significant abnormal safety laboratory values at the SEAD2&#xD;
             screening visit&#xD;
&#xD;
          -  Have any clinically significant abnormal findings on vital signs measurements, or on&#xD;
             physical or neurological examination at the SEAD2 screening visit&#xD;
&#xD;
          -  Use any type of systemic estrogen or testosterone replacement therapy&#xD;
&#xD;
          -  Has participated in another clinical trial or received any investigational drug or&#xD;
             investigational therapy within 30 days before the screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell Swerdlow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical and Translational Science Unit</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Russell Swerdlow</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Equol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>June 21, 2022</submitted>
    <returned>July 13, 2022</returned>
    <submitted>August 19, 2022</submitted>
    <returned>September 15, 2022</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

